Alison Y. Zhang

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis, Andrew Martin, Martin R. Stockler et al. · New England Journal of Medicine · 2019 · 1.5K citations

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet · 2021 · 1K citations

Urology, Oncology, Genitourinary Cancer +7

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

James P Buteau, Andrew Martin, Louise Emmett et al. · The Lancet Oncology · 2022 · 239 citations

Biomarker (Medicine), Prognostic Biomarkers, Urology +7

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

Christopher J. Sweeney, Andrew Martin, Martin R. Stockler et al. · The Lancet Oncology · 2023 · 175 citations

Urology, Oncology, Genitourinary Cancer +7

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Shubham Pant, Martin Schüler, Gopa Iyer et al. · The Lancet Oncology · 2023 · 175 citations · Full text

Fgfr Alterations, Medicine, Pathology +7